CompletedPhase 3ACTRN12610000849099

A study of the acute cognitive and neurocognitive effects of Panax Quinquefolius (American Ginseng) in middle aged volunteers.

A study of the acute cognitive and neurocognitive effects of Panax Quinquefolius in healthy middle aged volunteers.

Sponsor

Naturex

Enrollment

50 participants

Start Date

Jun 22, 2010

Study Type

Interventional

Conditions

Glucoregulatory Function Cognitive Function

Summary

The objective of the study is to determine the acute neurocognitive effects of a dose of Panax quinquefolius in healthy middle aged volunteers. The Cognitive Drug Research (CDR) computerized assessment battery will be used to evaluate effects of Ginseng on attention, working memory and secondary memory. Mood will also be assessed. Several paper and pencil questionnaires will also be completed which are designed to evaluate state and trait feelings of anxiety and depression and also to asses any symptomatology associated with the extract. Furthermore the neurophysiological effects will be measured using high spatial resolution electrical brain recordings measured by the Steady State Probe Topography technique (SSPT)

Eligibility

Sex: Both males and femalesMin Age: 40 YearssMax Age: 60 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether American Ginseng supplements can improve thinking, memory, and brain function in healthy middle-aged adults. It is for non-smoking men and women aged 40 to 60 who are in good health and not taking any medications or supplements.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Single dose of 200mg Panax Quinquefolius ( 11.65% saponin content; Rb1 (5.68%), Re (2.05%), Rc (1.86%), Rd (1.47%), Rb2 (.029%), Rg1 (.027%)) administered orally (capsule form). Participants have a 1

Single dose of 200mg Panax Quinquefolius ( 11.65% saponin content; Rb1 (5.68%), Re (2.05%), Rc (1.86%), Rd (1.47%), Rb2 (.029%), Rg1 (.027%)) administered orally (capsule form). Participants have a 1 week wash-out between the active treatment and placebo.